Andrew T Lenis1,2,3, Kian Asanad1, Maher Blaibel4, Nicholas M Donin1,2,3, Karim Chamie1,2,3. 1. David Geffen School of Medicine at the University of California Los Angeles. 2. Department of Urology, Health Services Research Group, David Geffen School of Medicine at UCLA, Los Angeles, California. 3. Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California. 4. University of California, Riverside School of Medicine, Riverside, California.
Abstract
INTRODUCTION: Intravesical bacillus Calmette-Guérin (BCG) therapy is the gold standard adjuvant treatment for patients with high-grade non-muscle-invasive bladder cancer (NMIBC). Despite the association between metabolic syndrome (MetS) and bladder cancer, the association between MetS and BCG failure is unknown. The objective of this study was to characterize disease recurrence following BCG in patients with and without MetS. METHODS: We retrospectively evaluated the records of patients undergoing TURBT at our institution in 2012-2015 for NMIBC and identified those who received adjuvant BCG therapy. MetS was defined as having three of four components: diabetes mellitus, hyperlipidemia, hypertension, or body mass index (BMI)≥30kg/m2. The primary outcome was recurrence or progression. Descriptive statistics, chi-squared analysis, Kaplan-Meier survival analysis, and Cox multivariable regression analyses were performed. RESULTS: High grade was present in 83/90 (92.2%) patients. MetS was present in 27/90 (30%) patients. Median follow-up was 20 months. On Kaplan-Meier analysis, patients with MetS had worse DFS compared with patient without MetS. On multivariable analysis, BMI≥30 kg/m2 was a significant predictor of recurrence or progression (HR 2.94, 95% CI: 1.43-6.03). Presence of MetS did not significantly affect the type of BCG failure. CONCLUSIONS: The association between MetS and failure to respond to BCG therapy is multifactorial but is in part associated with obesity. Elevated BMI is strongly associated with recurrence or progression. Further studies are warranted to investigate the relationship between increased adiposity and response to BCG, especially as other novel immunotherapeutic agents are likely to enter the NMIBC space.
INTRODUCTION: Intravesical bacillus Calmette-Guérin (BCG) therapy is the gold standard adjuvant treatment for patients with high-grade non-muscle-invasive bladder cancer (NMIBC). Despite the association between metabolic syndrome (MetS) and bladder cancer, the association between MetS and BCG failure is unknown. The objective of this study was to characterize disease recurrence following BCG in patients with and without MetS. METHODS: We retrospectively evaluated the records of patients undergoing TURBT at our institution in 2012-2015 for NMIBC and identified those who received adjuvant BCG therapy. MetS was defined as having three of four components: diabetes mellitus, hyperlipidemia, hypertension, or body mass index (BMI)≥30kg/m2. The primary outcome was recurrence or progression. Descriptive statistics, chi-squared analysis, Kaplan-Meier survival analysis, and Cox multivariable regression analyses were performed. RESULTS: High grade was present in 83/90 (92.2%) patients. MetS was present in 27/90 (30%) patients. Median follow-up was 20 months. On Kaplan-Meier analysis, patients with MetS had worse DFS compared with patient without MetS. On multivariable analysis, BMI≥30 kg/m2 was a significant predictor of recurrence or progression (HR 2.94, 95% CI: 1.43-6.03). Presence of MetS did not significantly affect the type of BCG failure. CONCLUSIONS: The association between MetS and failure to respond to BCG therapy is multifactorial but is in part associated with obesity. Elevated BMI is strongly associated with recurrence or progression. Further studies are warranted to investigate the relationship between increased adiposity and response to BCG, especially as other novel immunotherapeutic agents are likely to enter the NMIBC space.
Authors: Asaf Wyszynski; Sam A Tanyos; Judy R Rees; Carmen J Marsit; Karl T Kelsey; Alan R Schned; Eben M Pendleton; Maria O Celaya; Michael S Zens; Margaret R Karagas; Angeline S Andrew Journal: Cancer Date: 2013-10-10 Impact factor: 6.860
Authors: D L Lamm; B A Blumenstein; J D Crissman; J E Montie; J E Gottesman; B A Lowe; M F Sarosdy; R D Bohl; H B Grossman; T M Beck; J T Leimert; E D Crawford Journal: J Urol Date: 2000-04 Impact factor: 7.450
Authors: Christel Häggström; Tanja Stocks; Kilian Rapp; Tone Bjørge; Björn Lindkvist; Hans Concin; Anders Engeland; Jonas Manjer; Hanno Ulmer; Randi Selmer; Steinar Tretli; Göran Hallmans; Håkan Jonsson; Pär Stattin Journal: Int J Cancer Date: 2011-04-15 Impact factor: 7.396
Authors: Karim Chamie; Eric Ballon-Landa; Timothy J Daskivich; Jeffrey C Bassett; Julie Lai; Jan M Hanley; Badrinath R Konety; Mark S Litwin; Christopher S Saigal Journal: Urol Oncol Date: 2014-11-07 Impact factor: 3.498
Authors: Maurizio Brausi; Jorg Oddens; Richard Sylvester; Aldo Bono; Cees van de Beek; George van Andel; Paolo Gontero; Levent Turkeri; Sandrine Marreaud; Sandra Collette; Willem Oosterlinck Journal: Eur Urol Date: 2013-07-24 Impact factor: 20.096
Authors: Matteo Ferro; Octavian Sabin Tătaru; Gennaro Musi; Giuseppe Lucarelli; Abdal Rahman Abu Farhan; Francesco Cantiello; Rocco Damiano; Rodolfo Hurle; Roberto Contieri; Gian Maria Busetto; Giuseppe Carrieri; Luigi Cormio; Francesco Del Giudice; Alessandro Sciarra; Sisto Perdonà; Marco Borghesi; Carlo Terrone; Evelina La Civita; Pierluigi Bove; Riccardo Autorino; Matteo Muto; Nicolae Crisan; Michele Marchioni; Luigi Schips; Francesco Soria; Daniela Terracciano; Rocco Papalia; Felice Crocetto; Biagio Barone; Giorgio Ivan Russo; Stefano Luzzago; Giuseppe Mario Ludovico; Mihai Dorin Vartolomei; Francesco Alessandro Mistretta; Vincenzo Mirone; Ottavio de Cobelli Journal: Diagnostics (Basel) Date: 2022-02-25